Xvivo Perfusion AB (LTS:0RKL)
kr 471.13141 -2.4818 (-0.52%) Market Cap: 15.12 Bil Enterprise Value: 14.69 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Xvivo Perfusion AB Corporate Analyst Meeting Transcript

Sep 21, 2022 / 12:00PM GMT
Release Date Price: kr163.4 (-2.51%)
Dag Andersson;President;CEO

& -

Good afternoon or good morning. Welcome to XVIVO Capital Markets Day 2022. Last year, we held our first Capital Markets Day here in Gothenburg. And this year, we have chosen a 100% digital format for the 2 hours which we will be spending together. We have more than 100 listeners this year versus 80 last year. So welcome, all of you.

Please remember that the Q&A session will be at the end of the presentations. So note down any questions you might have. The agenda has been communicated, and we will give you an insight into the key components of our strategy and also some short- to mid-term actions. I have promised more quantitative insights into what we expect to deliver by 2027 compared with what we presented at last year's Capital Markets Day, and you will get some more quantitative insights.

So let's get started. For those of you who have limited knowledge about XVIVO and our industry, XVIVO operates in the field of transplantation. And our core business is within organ recovery, organ preservation and organ evaluation for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot